Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

PHASE3CompletedINTERVENTIONAL
Enrollment

406

Participants

Timeline

Start Date

December 5, 2017

Primary Completion Date

January 29, 2020

Study Completion Date

September 7, 2020

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

efpeglenatide (SAR439977)

"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"

DRUG

placebo

"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"

Trial Locations (54)

12627

Investigational Site Number 2760005, Berlin

19040

Investigational Site Number 8400008, Hatboro

21009

Investigational Site Number 8040004, Vinnitsa

27215

Investigational Site Number 8400028, Burlington

28401

Investigational Site Number 8400031, Wilmington

30044

Investigational Site Number 8400025, Lawrenceville

32720

Investigational Site Number 8400010, DeLand

33012

Investigational Site Number 8400006, Hialeah

33409

Investigational Site Number 8400032, West Palm Beach

35205

Investigational Site Number 8400004, Birmingham

43537

Investigational Site Number 8400013, Maumee

60313

Investigational Site Number 2760003, Frankfurt am Main

60612

Investigational Site Number 8400034, Chicago

64128

Investigational Site Number 8400033, Kansas City

68503

Investigational Site Number 8400018, Lincoln

75010

Investigational Site Number 8400017, Carrollton

75024

Investigational Site Number 8400019, Plano

75230

Investigational Site Number 8400030, Dallas

77074

Investigational Site Number 8400015, Houston

78154

Investigational Site Number 8400023, Schertz

78218

Investigational Site Number 8400020, San Antonio

78229

Investigational Site Number 8400016, San Antonio

Investigational Site Number 8400027, San Antonio

85306

Investigational Site Number 8400005, Glendale

89106

Investigational Site Number 8400062, Las Vegas

89109

Investigational Site Number 8400021, Las Vegas

90057

Investigational Site Number 8400009, Los Angeles

91303

Investigational Site Number 8400003, Canoga Park

91356

Investigational Site Number 8400024, Tarzana

91405

Investigational Site Number 8400026, Van Nuys

91767

Investigational Site Number 8400029, Pomona

91911

Investigational Site Number 8400007, Chula Vista

91942

Investigational Site Number 8400011, La Mesa

08302

Investigational Site Number 8400001, Bridgeton

84117-7054

Investigational Site Number 8400002, Holladay

04103

Investigational Site Number 2760001, Leipzig

80-382

Investigational Site Number 6160005, Gdansk

81-537

Investigational Site Number 6160004, Gdynia

40-040

Investigational Site Number 6160007, Katowice

31-501

Investigational Site Number 6160002, Krakow

60-702

Investigational Site Number 6160006, Poznan

01-192

Investigational Site Number 6160003, Warsaw

50-381

Investigational Site Number 6160001, Wroclaw

02002

Investigational Site Number 8040003, Kyiv

03037

Investigational Site Number 8040001, Kyiv

03049

Investigational Site Number 8040002, Kyiv

B15 2SQ

Investigational Site Number 8260005, Birmingham

CF15 9SS

Investigational Site Number 8260004, Cardiff

PR7 7NA

Investigational Site Number 8260007, Chorley

G20 0SP

Investigational Site Number 8260008, Glasgow

NE46 1QJ

Investigational Site Number 8260001, Hexham

L22 0LG

Investigational Site Number 8260003, Liverpool

M15 6SX

Investigational Site Number 8260006, Manchester

RG2 0TG

Investigational Site Number 8260002, Reading

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT03353350 - Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise | Biotech Hunter | Biotech Hunter